Akero Therapeutics, Inc. (AKRO)

NASDAQ: AKRO · IEX Real-Time Price · USD
26.65
+0.09 (0.34%)
Sep 27, 2022 4:00 PM EDT - Market closed
0.34%
Market Cap 1.21B
Revenue (ttm) n/a
Net Income (ttm) -110.19M
Shares Out 45.28M
EPS (ttm) -3.20
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 346,529
Open 26.92
Previous Close 26.56
Day's Range 26.37 - 27.40
52-Week Range 7.52 - 29.78
Beta 0.56
Analysts Buy
Price Target 45.39 (+70.3%)
Earnings Date Nov 10, 2022

About AKRO

Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regulates metabolism of lipids, carbohydrates, and proteins throughout the body. It also conducts a Phase 2a clinical trial, the BALANCED study, to evaluate EFX in the treatment of biopsy-confirmed NASH patien... [Read more...]

Industry Biotechnology
IPO Date Jun 20, 2019
Employees 37
Stock Exchange NASDAQ
Ticker Symbol AKRO
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 12 analysts, the average rating for AKRO stock is "Buy." The 12-month stock price forecast is 45.39, which is an increase of 70.32% from the latest price.

Price Target
$45.39
(70.32% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Akero Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Full Exercise of Underwriters' Op...

SOUTH SAN FRANCISCO, Calif., Sept. 19, 2022 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabol...

1 week ago - GlobeNewsWire

Here Are 10 Biotech Stocks — Including Catalyst And Viridian — That Would Have Netted You $10,000 More This Year

The double-digit run for biotech stocks off a June bottom is great — until you realize you could've netted more by investing in the best. The post Here Are 10 Biotech Stocks — Including Catalyst And Vir...

1 week ago - Investors Business Daily

Akero Therapeutics Announces Pricing of Upsized Public Offering of Common Stock

SOUTH SAN FRANCISCO, Calif., Sept. 14, 2022 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabol...

1 week ago - GlobeNewsWire

Akero Therapeutics (AKRO) Up on Positive Data from NASH Study

Akero Therapeutics (AKRO) reports positive top-line data from a mid-stage study evaluating its lead candidate, efruxifermin (EFX), in patients with NASH, fibrosis stage 2 or 3 (F2-F3). Stock up.

1 week ago - Zacks Investment Research

Akero Therapeutics Announces Proposed Public Offering of Common Stock

SOUTH SAN FRANCISCO, Calif., Sept. 13, 2022 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabol...

2 weeks ago - GlobeNewsWire

Why Akero Therapeutics Stock Is on Fire Today

The biotech's experimental NASH drug hit the mark in a key phase 2b trial.

2 weeks ago - The Motley Fool

Why Is Akero Therapeutics (AKRO) Stock Up 120% Today?

Akero Therapeutics (NASDAQ: AKRO ) stock is soaring 120% and is one of today's top trending tickers on sites like Yahoo Finance. The rally was sparked by the company's release of positive data on its dr...

2 weeks ago - InvestorPlace

Akero Therapeutics Wows Investors With Unexpected Win For Hepatitis Treatment

Akero wowed investors Tuesday with midstage test results for a hepatitis treatment, and the biotech stock skyrocketed by triple digits. The post Akero Therapeutics Wows Investors With Unexpected Win For...

2 weeks ago - Investors Business Daily

Peloton's Shake-Up Continues, but This Tiny Stock Doubled Early Tuesday

As the connected fitness equipment maker keeps going through turmoil, good news helped lift a largely unknown company's share price.

Other symbols: PTON
2 weeks ago - The Motley Fool

Akero's experimental NASH drug meets the primary endpoint in a clinical trial

Shares of Akero Therapeutics Inc. AKRO, +4.78% soared 101.1% in premarket trading on Tuesday after the company said its experimental treatment for nonalcoholic steatohepatitis met a primary and secondar...

2 weeks ago - Market Watch

In Akero Therapeutics' Phase 2b HARMONY Study, Both the 50mg and 28mg EFX Doses Achieved Statistical Significance on ...

50mg (41%) and 28mg (39%) groups demonstrated ≥1 stage improvement in fibrosis without worsening of NASH, double the placebo rate (20%)

2 weeks ago - GlobeNewsWire

Akero Therapeutics to Present Results from Phase 2b HARMONY Trial Investigating Efruxifermin in Patients with Pre-Cir...

Investor webcast on Tuesday, September 13 at 8:00 a.m. ET to present clinical data Investor webcast on Tuesday, September 13 at 8:00 a.m. ET to present clinical data

2 weeks ago - GlobeNewsWire

Akero Therapeutics (AKRO) Up on Positive NASH Study Data

Akero Therapeutics (AKRO) announces positive data from third cohort of its mid-stage study evaluating efruxifermin (EFX) in NASH. Stock up.

1 month ago - Zacks Investment Research

Study Published in JHEP Reports Shows Efruxifermin Rapidly Improved Fibrosis in Cirrhotic NASH patients After 16 Week...

33% improved by one fibrosis stage without worsening of NASH; 25% of patients treated with efruxifermin showed NASH resolution

1 month ago - GlobeNewsWire

Akero Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Update

SOUTH SAN FRANCISCO, Calif., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metaboli...

1 month ago - GlobeNewsWire

Akero Therapeutics Presents Analysis at the 2022 International Liver Congress Showing that Efruxifermin Improved Hist...

Post hoc analysis shows potential for EFX to treat patients at highest genetic risk for progressive and advanced NASH Post hoc analysis shows potential for EFX to treat patients at highest genetic risk ...

3 months ago - GlobeNewsWire

Akero Therapeutics Shares Surge After Equity Investment From This Famed Large Cap Biopharma

Akero Therapeutics Inc (NASDAQ: AKRO) announced a $25 million equity investment by Pfizer Inc (NYSE: PFE) at $9.90 per share.  The company also announced a term loan facility providing Akero with access...

3 months ago - Benzinga

Akero Therapeutics Announces Two Financing Transactions with Pfizer Inc. and Hercules Capital, Inc. Providing Access ...

$25 Million Equity Investment by Pfizer at $9.90 Per Share

3 months ago - GlobeNewsWire

Akero Therapeutics to Present at Keystone Symposium on Efruxifermin as a Therapy for NASH

Presentations to highlight the association of EFX's antifibrotic effects as scored by histology with consistent reductions in biomarkers of liver collagen synthesis Presentations to highlight the associ...

3 months ago - GlobeNewsWire

Akero Therapeutics to Present at the Jefferies Global Healthcare Conference

SOUTH SAN FRANCISCO, Calif., June 01, 2022 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metaboli...

3 months ago - GlobeNewsWire

Akero Therapeutics Reports First Quarter 2022 Financial Results

Akero Remains on Track to Report Phase 2b HARMONY Study Results in the Third Quarter of This Year Akero Remains on Track to Report Phase 2b HARMONY Study Results in the Third Quarter of This Year

4 months ago - GlobeNewsWire

Akero Therapeutics to Present at Upcoming Healthcare Conferences in May

SOUTH SAN FRANCISCO, May 02, 2022 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic disease...

4 months ago - GlobeNewsWire

Akero Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results

Akero Remains on Track to Report Phase 2b HARMONY Study Results in the Third Quarter of This Year Akero Remains on Track to Report Phase 2b HARMONY Study Results in the Third Quarter of This Year

7 months ago - GlobeNewsWire

Akero Therapeutics Completes Enrollment of Phase 2b HARMONY Study in Pre-Cirrhotic NASH Patients

SOUTH SAN FRANCISCO, Calif., Feb. 08, 2022 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metaboli...

7 months ago - GlobeNewsWire

Is Akero Therapeutics, Inc. (AKRO) Outperforming Other Medical Stocks This Year?

Here is how Akero Therapeutics, Inc. (AKRO) and Butterfly Network, Inc. (BFLY) have performed compared to their sector so far this year.

8 months ago - Zacks Investment Research